echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui SHR-1905 was approved as the third monoclonal antibody in the field of clinical asthma

    Hengrui SHR-1905 was approved as the third monoclonal antibody in the field of clinical asthma

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 12, the official website of CDE showed that Hengrui's Class 1 new drug SHR-1905 injection was approved for clinical use, and its indication is asthma.


    At present, Hengrui has 2 monoclonal antibody drugs intended for asthma in the clinical stage, namely SHR-1819 targeting IL-4R and SHR-1703 targeting IL-5.


    The fastest progress in the world is the TSLP-targeted monoclonal antibody Tezepelumab that Amgen and AstraZeneca collaborated on.


    The curative effect of existing biological drugs is associated with increased eosinophil content, which is observed in 60% of patients with moderate to severe asthma.


    TSLP is an epithelial cytokine produced in response to pro-inflammatory stimuli (such as lung allergens, viruses, and other pathogens).


    According to the Insight database, AstraZeneca has currently carried out a phase III clinical trial of Tezepelumab for asthma in China.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.